| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Crinetics Pharmaceuticals, Inc.$83.58
-0.04 (-0.05%)
C 49Pipeline Score Overvalued Pharma · Commercial
Market Cap
3.88 B
EPS
-5.13
P/E Ratio
-
Value Trade
28.32 M
SEC Financials
Q1 2026Dilution Risk
Revenue
10.73 M
R&D Expenses
100.08 M
Operating CF
-124.70 M
Total Assets
1.40 B
Total Liabilities
120.68 M
Equity
1.28 B
D/E Ratio
12,345
-3.21 %
Week
-5.83 %
1 Month
-16.23 %
3 Month
-11.56 %
6 Month
118.4 %
5 Year
91.17 %
All Time
Cash Data
Cash Position
1.29 B
Monthly Burn
41.57 M
Runway
29.2 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
7.36 M
52 Week Range
25.83 - 57.99
% held by Insiders
6.19 %
% held by Institutions
112.81 %
Enterprise Value
2.64 B
Total Shares
105.45 M
Short %
13.75 %
Float Shares
100.71 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Crinetics Pharmaceuticals, Inc.
495Total events
13Upcoming
105Tier-1 (high impact)
2017 – 2026Coverage
Upcoming catalysts 13
2025-H2
T2First Patient Dosed
First participants randomized in Phase 2/3 BALANCE-CAH study in pediatrics
Event history 482
Jun 15, 2026
◆Poster PresentationPaltusotineApprovedPresentation
Real-World Biochemical Control in Acromegaly: Insights from US Claims and Laboratory Data
acromegalysource ↗
Jun 15, 2026
◆Poster PresentationatumelnantPresentation
Model-Informed Atumelnant Dose Selection for a Phase 3 Study in Adult Patients With Classic Congenital Adrenal Hyperplasia
congenital adrenal hyperplasiasource ↗
Jun 14, 2026
◆Oral PresentationatumelnantPresentation
‘Block And Replace’ Atumelnant (CRN04894) And Physiologic Hydrocortisone Replacement Rapidly Controls Hypercortisolism In ACTH-dependent Cushing Syndrome
ACTH-dependent Cushing's syndromesource ↗
Jun 14, 2026
▲Oral PresentationPALSONIFYApprovedPresentation
Oral presentation of up to 2-year OLE data from PATHFNDR-1 and PATHFNDR-2 at ENDO 2026
acromegalysource ↗
Jun 14, 2026
◆Oral PresentationPaltusotineApprovedPresentation
Efficacy and Safety of Once-Daily Oral Paltusotine in Patients with Acromegaly: Up to 2 years in the PATHFNDR-1 and PATHFNDR-2 Open-Label Extension Studies
acromegalysource ↗
Jun 14, 2026
◆Poster PresentationPaltusotineApprovedPresentation
Long-Term Safety and Efficacy of Once-Daily Oral Paltusotine in Combination With Cabergoline for the Treatment of Patients With Acromegaly
acromegalysource ↗
Jun 3, 2026
◆R&D DayPresentation
Crinetics management to participate in Jefferies Global Healthcare Conference 2026
May 7, 2026
●Quarterly UpdateCorporate
Reported Q1 2026 financial results with PALSONIFY net product revenue of $10.3 million
May 2026
▲Partnership / LicenseCorporate
Entered exclusive license agreement with Ohio University for preclinical growth hormone receptor antagonist
acromegalysource ↗
Apr 27, 2026
▲EU ApprovalPALSONIFYApprovedEx-US Regulatory
European Commission approval of PALSONIFY for acromegaly
acromegalysource ↗
Apr 2026
▲EU ApprovalPALSONIFYApprovedEx-US Regulatory
European Commission approved PALSONIFY for adult acromegaly
acromegalysource ↗
Apr 2026
●NDA SubmissionPaltusotineApprovedRegulatory Filing
SKK submitted NDA in Japan for paltusotine for acromegaly
acromegalysource ↗
Drug Pipeline Intelligence
C49
Pipeline Score $1.0B
Pipeline ValueOvervalued
Valuation Signal7
Drugs Scored0.3x
rNPV / MCap Top 74%
Small Cap (rank 238 of 911)
Percentile RankCrinetics Pharmaceuticals, Inc. carries a moderate pipeline score (49/100), with $1.5B risk-adjusted pipeline value, led by Paltusotine in Carcinoid Syndrome (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Paltusotine Small molecule | Acromegaly | Phase 3 | NCT04261712 | 74% | $883M | ACTIVE NOT_RECRUITING | 272 | SLOW | D (25) | Mar 31, 2028 | LOW_RISK | LOW Jul 8, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
atumelnant Orphan | Congenital Adrenal Hyperplasia (CAH) | Phase 2 | 2026-06-14 | A4 change: -67%; participants achieving normal doses: 88%; participants completed: 8 Read More | Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Read More | |
atumelnant Orphan | Congenital Adrenal Hyperplasia (CAH) | Phase 2 | 2026-06-14 | A4 change: -67%; participants achieving normal doses: 88%; participants completed: 8 Read More | Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Read More | |
atumelnant Orphan | Congenital Adrenal Hyperplasia (CAH) | Phase 2 | 2026-06-14 | A4 change: -67%; participants achieving normal doses: 88%; participants completed: 8 Read More | Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CRNX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CRNX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CRNXCrinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026
Crinetics Pharmaceuticals will report its second quarter 2026 financial results on August 4, 2026, after market close. A conference call will follow at 4:30 p.m. ET for management to discuss the results and provide a business update. The company focuses on developing therapies for endocrine diseases and has a robust pipeline of investigational candidates.
Read more →CRNXCrinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
Crinetics Pharmaceuticals presented promising results from its Phase 2 trial of atumelnant for treating congenital adrenal hyperplasia (CAH) at ENDO 2026. The oral presentation highlighted significant reductions in androgen levels, with 88% of participants achieving normal glucocorticoid doses. The drug was well tolerated, showing no severe adverse events, and the efficacy in lowering glucocorticoid supplementation could represent a significant advancement in treatment options. Further Phase 3 trials are already underway to explore the full potential of atumelnant.
Read more →CRNXCrinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
Crinetics Pharmaceuticals presented new long-term data on PALSONIFY (paltusotine) at the ENDO 2026 conference, indicating effective and durable control of acromegaly symptoms and IGF-1 levels after two years of treatment. The data showed that patients transitioning from injectable somatostatin receptor ligands to the oral formulation maintained stable symptoms and reduced pituitary tumor volumes. Additionally, combination therapy with cabergoline demonstrated improved biochemical control. Overall, the findings suggest PALSONIFY as a promising option for patients with acromegaly who have had inadequate responses to other treatments.
Read more →CRNXEveryday Advocacy: The Small Moments That Shape a Patient’s Journey
Crinetics has launched the Everyday Advocacy initiative aimed at empowering patients with endocrine conditions. This program focuses on enhancing patient engagement through education and resources tailored to everyday experiences. It includes digital tools, workshops, and a mobile app to help patients better prepare for medical conversations. The initiative is designed to evolve based on patient feedback and community needs.
Read more →CRNX▼ -5.5%on this newsshared move
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
Crinetics Pharmaceuticals will present six abstracts at ENDO 2026, showcasing data on PALSONIFY (paltusotine) and atumelnant. The presentations include long-term efficacy and safety data for PALSONIFY in acromegaly, as well as Phase 2 results for atumelnant in congenital adrenal hyperplasia. The company aims to redefine treatment options for endocrine diseases.
Read more →CRNX▼ -5.5%on this newsshared move
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities
Crinetics Pharmaceuticals has launched the Everyday Advocacy initiative aimed at empowering individuals with endocrine diseases. This program, developed in collaboration with prominent patient organizations, focuses on providing education, tools, and resources to enhance patient self-advocacy and healthcare team interactions. A specific mobile app, workshops, and a commitment to expand into other endocrine conditions are key components of the initiative. The program illustrates Crinetics' dedication to patient-focused innovation in treating endocrine disorders.
Read more →CRNXCrinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
Crinetics Pharmaceuticals will participate in the Jefferies Global Healthcare Conference from June 2-4, 2026, in New York. Management will hold 1x1 meetings with investors on June 3, 2026. The company focuses on developing treatments for endocrine diseases and has a robust pipeline, including its first commercial product, PALSONIFY™.
Read more →CRNXCrinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reported strong financial results for Q1 2026, with $10.3 million in net product revenue from PALSONIFY. The company recorded 232 enrollment forms and witnessed growing adoption among healthcare providers. The European Commission approved PALSONIFY for treating acromegaly, and management remains optimistic about its long-term commercial prospects. However, the company also reported a significant net loss and increased R&D expenses, indicating potential financial challenges ahead.
Read more →CRNXA New Chapter for Acromegaly Care in the European Union
The European Commission has approved the first once-daily oral therapy for acromegaly, marking a significant advancement in patient care. This approval highlights the need for treatment options that align with patients' lifestyles and improves long-term management of the condition. Crinetics is committed to expanding access to this therapy in Europe, starting with Germany and Austria.
Read more →CRNXCrinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
Crinetics Pharmaceuticals has received European Commission approval for PALSONIFY (paltusotine), the first once-daily oral treatment for acromegaly in adults. This approval is based on positive results from two pivotal Phase 3 studies, demonstrating safety and efficacy in both treated and untreated patients. The company plans to launch PALSONIFY initially in Germany and Austria, marking its first regulatory approval outside the U.S.
Read more →CRNXNeutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer
Neutrolis Inc. has appointed Caren Deardorf as Chief Business & Strategy Officer. With over 30 years of experience, she will lead the company's corporate and pipeline strategy, business development, and early commercial strategy. Deardorf's background includes significant roles in various biotech firms and a history of successful product launches.
Read more →CRNXCrinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
Crinetics Pharmaceuticals will announce its first quarter 2026 financial results on May 7, 2026, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and provide a business update. The company is known for its innovative treatments for endocrine diseases, including the FDA-approved Paltusotine.
Read more →CRNX▼ -7.3%on this news
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
Crinetics Pharmaceuticals has submitted a Marketing Authorization Application for Palsonify (paltusotine) to Brazil's ANVISA for treating acromegaly. This application is backed by data from 18 clinical trials, including two successful Phase 3 studies. Palsonify is already approved in the US and has received a positive opinion in Europe, highlighting its potential impact on acromegaly treatment.
Read more →CRNXCrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update PALSONIFY (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with 200 Enrollment
Crinetics Pharmaceuticals reported its financial results for Q4 and full year 2025, showcasing a strong start with its product PALSONIFY, which generated $5.4 million in net revenues. The company also received a positive opinion from the EMA for PALSONIFY's marketing authorization, affirming its market potential. Additionally, promising data from the Phase 2 study of atumelnant was reported, highlighting its potential as an effective treatment. However, the company faced significant losses and an increase in research and development expenses during this period.
Read more →CRNXCrinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March 2026
Crinetics Pharmaceuticals announced its participation in two investor conferences in March 2026. The TD Cowen 46th Annual Health Care Conference will take place in Boston, while the Leerink Annual Global Healthcare Conference is scheduled for Miami. Management will be available for one-on-one meetings with investors at both events.
Read more →CRNXCrinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Crinetics Pharmaceuticals will announce its fourth quarter and full year 2025 financial results on February 26, 2026. A conference call will follow to discuss the results and provide a business update. The company is known for its commitment to developing therapies for endocrine diseases, with a strong pipeline including Paltusotine and other investigational candidates.
Read more →CRNXCrinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Crinetics Pharmaceuticals has initiated the BALANCE-CAH Phase 2/3 trial for atumelnant, an ACTH receptor antagonist aimed at treating classic congenital adrenal hyperplasia (CAH) in pediatric patients. The trial will assess the drug's safety, efficacy, and pharmacokinetics, addressing a significant unmet medical need in this population. Atumelnant is the first small molecule of its kind in late-stage development.
Read more →CRNXCrinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 12, 2026
Crinetics Pharmaceuticals announced the granting of stock options and RSUs to new non-executive employees as part of its 2021 Inducement Plan. This initiative aims to attract talent in line with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $53.25 and will vest over four years, contingent on continued employment.
Read more →CRNX▲ +16.1%on this news
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Crinetics Pharmaceuticals has announced the pricing of a public offering of 7,620,000 shares of its common stock at $45.95 per share, aiming to raise approximately $350 million. The proceeds will be used to support the launch of PALSONIFY™, along with funding research and development for its other product candidates. The offering is expected to close on or about January 8, 2026, subject to customary closing conditions. Major financial institutions, including Leerink Partners and J.P. Morgan, are managing the offering.
Read more →CRNXCrinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock - January 5, 2026
Crinetics Pharmaceuticals announced a proposed public offering of $350 million in common stock, with an additional $52.5 million option for underwriters. The proceeds will fund commercial activities for PALSONIFY™, research and development, and other corporate purposes. The offering is subject to market conditions and will be conducted under a shelf registration statement with the SEC.
Read more →CRNXCrinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals reported a successful launch of PALSONIFY, generating over $5 million in preliminary revenue for Q4 2025. The company also announced positive results from its Phase 2 trial of atumelnant, which demonstrated significant reductions in androstenedione levels and allowed a majority of participants to lower their glucocorticoid doses. The treatment was well-tolerated with no serious adverse events reported.
Read more →CRNXCrinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals will hold a conference call on January 5, 2026, to update on PALSONIFY commercialization and share topline results from the fourth cohort of the Phase 2 trial of atumelnant for congenital adrenal hyperplasia. The company is focused on developing therapies for endocrine diseases, with a strong pipeline including atumelnant and PALSONIFY.
Read more →CRNXCrinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
Crinetics Pharmaceuticals, Inc. announced a proposed underwritten public offering of $350 million of its common stock, with an additional option for underwriters to purchase more shares. The company intends to use the funds to enhance its commercial activities and support the development of its therapeutic candidates. The offering is subject to market conditions and may or may not be completed as initially planned. Crinetics is focused on endocrine diseases and has several investigational programs currently in various stages of development.
Read more →CRNXJANUARY 2026 Beyond Building Innovation the Premier to Impact: Endocrinology Business J.P. Morgan Healthcare Conference Angela Forward Looking Statements and Legal Disclaimers Forward Looking Statements: This contained p
Crinetics Pharmaceuticals recently participated in the J.P. Morgan Healthcare Conference, where they emphasized the advancements made in their endocrinology business. The company highlighted the launch of PALSONIFY and its promising pipeline, which includes ongoing Phase 3 studies for various indications. Despite demonstrating early success and having substantial financial backing, the presentation underscored the inherent risks associated with forward-looking statements and the uncertainties surrounding drug approvals and clinical development timelines.
Read more →CRNX▼ -5.3%on this news
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
Crinetics Pharmaceuticals announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 13, 2026. CEO Scott Struthers will present at the event, highlighting the company's focus on innovative treatment options for endocrine diseases. The conference serves as an opportunity for Crinetics to engage with investors and showcase its advancements in drug development.
Read more →CRNXCrinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 10, 2025
Crinetics Pharmaceuticals announced the granting of stock options and RSUs to nine new non-executive employees under its 2021 Inducement Plan. This initiative aims to attract talent in line with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $48.06 per share and will vest over four years, contingent on continued employment.
Read more →CRNXCrinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Crinetics Pharmaceuticals announced the dosing of the first patient in its CALM-CAH Phase 3 trial for atumelnant, an ACTH receptor antagonist aimed at treating congenital adrenal hyperplasia (CAH). The study will evaluate the drug's effectiveness in normalizing adrenal androgen levels and reducing glucocorticoid levels. Atumelnant is notable as the first small molecule in late-stage clinical development for this condition, and it recently received Orphan Drug Designation from the FDA. The company aims to address significant unmet needs in the management of CAH.
Read more →CRNXCrinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
Crinetics Pharmaceuticals has announced that the first patient has been dosed in the Phase 1/2 clinical trial evaluating CRN09682, aimed at treating neuroendocrine tumors and other SST2-expressing solid tumors. This investigational therapy represents a novel nonpeptide drug conjugate designed to selectively target SST2-positive tumor cells. The trial will assess safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. Up to 150 participants will be enrolled, with the study's phases evaluating maximum tolerated doses and effectiveness.
Read more →CRNXCrinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
Crinetics Pharmaceuticals has announced the randomization of the first patient in its pivotal Phase 3 CAREFNDR trial evaluating the oral drug paltusotine for carcinoid syndrome associated with neuroendocrine tumors. This trial builds upon positive results from a Phase 2 study showing rapid improvements in symptom management. The study aims to enroll 141 participants and measure the efficacy and safety of paltusotine over an extended period, reflecting Crinetics' commitment to addressing unmet medical needs in patients with carcinoid syndrome.
Read more →CRNXCrinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announced the grant of stock options and restricted stock units to 11 new employees as part of their 2021 Employment Inducement Incentive Award Plan. This move is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to the company. The stock options are priced at $41.45 per share and will vest over four years.
Read more →CRNX▼ -8%on this newsshared move
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reported strong third quarter results, highlighting the successful launch of Palsonify for acromegaly treatment. The company noted positive early feedback from healthcare providers and patients, along with favorable reimbursement trends. Crinetics reiterated its financial stability, projecting a cash runway into 2029 while advancing multiple clinical trials in its pipeline.
Read more →CRNXNANETS 2025: Reimagining Treatment for Carcinoid Syndrome
Crinetics is developing paltusotine, an oral SST2 agonist for carcinoid syndrome, which aims to improve both symptom management and patient quality of life. Recent data presented at NANETS 2025 showed a 74% progression-free survival rate after one year of treatment. The company emphasizes its commitment to advancing endocrine science and enhancing patient outcomes.
Read more →CRNXCrinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
Crinetics Pharmaceuticals will present three abstracts at the 2025 North American Neuroendocrine Tumor Society Annual Meeting. Highlights include progression-free survival data from a Phase 2 study of paltusotine for carcinoid syndrome, showing a 74% survival rate after one year. The meeting will also cover new clinical trials for paltusotine and the investigational drug CRN09682.
Read more →CRNXCrinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announced the granting of stock options and restricted stock units (RSUs) to new employees as part of its 2021 Employment Inducement Incentive Award Plan. A total of 78,975 stock options and 54,475 RSUs were awarded to 20 new non-executive employees, with vesting schedules over four years contingent upon continued employment. This initiative aligns with Nasdaq Listing Rule 5635(c)(4), emphasizing Crinetics' strategic move to attract talent while enhancing its employee compensation framework.
Read more →CRNXCrinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
Crinetics Pharmaceuticals, Inc. announced it will report its third quarter financial results on November 6, 2025, after market closure. Management plans to host a conference call at 4:30 p.m. ET to discuss these results and provide a business update. The company has a focus on developing treatments for endocrine diseases and has various investigational products in late-stage development, including programs for acromegaly and congenital adrenal hyperplasia.
Read more →CRNXA New Era in Acromegaly Care: Putting Patients at the Center
Crinetics Pharmaceuticals has launched PALSONIFY, a new oral treatment for adults with acromegaly who cannot undergo surgery. This therapy aims to alleviate the treatment burden faced by patients, emphasizing patient-centered care and accessibility. While PALSONIFY offers a promising alternative, it is crucial to consider potential side effects and the need for ongoing monitoring.
Read more →CRNX▲ +27.9%on this news
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
Crinetics Pharmaceuticals announced FDA approval for PALSONIFY (paltusotine), the first once-daily oral treatment for adults with acromegaly who have not responded adequately to surgery. The approval is based on positive results from two pivotal Phase 3 trials, demonstrating effective biochemical control and reduced symptoms. PALSONIFY is set to be available in the U.S. in early October 2025.
Read more →CRNXCrinetics Announces FDA Approval of PALSONIFY TM (paltusotine) for the Treatment of Adults with Acromegaly Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy app
Crinetics Pharmaceuticals has received FDA approval for PALSONIFY (paltusotine), a novel once-daily oral therapy for adults with acromegaly. This approval is based on positive outcomes from two pivotal Phase 3 trials demonstrating the drug's efficacy and safety profile. PALSONIFY represents a significant advancement in the treatment options for patients who have insufficient responses to surgery or are not candidates for surgical intervention. Crinetics emphasizes its commitment to patient advocacy and education through the newly launched CrinetiCARE program.
Read more →CRNXCrinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals, Inc. (CRNX) has announced the granting of non-qualified stock options and restricted stock units (RSUs) to 20 new non-executive employees under its 2021 Employment Inducement Incentive Award Plan. The grants total 62,475 shares of stock options and 43,800 RSUs, with vesting schedules based on continued employment. This initiative is part of compliance with Nasdaq's Listing Rule 5635(c)(4), aiming to attract new talent to the company. The exercise price for stock options aligns with the current market value of CRNX shares.
Read more →CRNXCrinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
Crinetics Pharmaceuticals announced that the FDA has granted Orphan Drug Designation for atumelnant, a novel ACTH receptor antagonist aimed at treating classic congenital adrenal hyperplasia (CAH). The designation highlights the significant unmet medical need for CAH patients. Positive results from the Phase 2 TouCAHn trial showed substantial reductions in key biomarkers, paving the way for upcoming Phase 3 trials.
Read more →CRNXCrinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals has announced the grant of stock options and restricted stock units (RSUs) to 27 new non-executive employees as part of its 2021 Employment Inducement Incentive Award Plan. The grants, totaling 75,850 stock options and 53,400 RSUs, are in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $26.85 per share and vest over four years, while the RSUs also follow a similar vesting schedule. This move aims to attract new talent and incentivize employee performance.
Read more →CRNXCrinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY (paltusotine) New Dru
Crinetics Pharmaceuticals has reported its financial results for Q2 2025, indicating a continued focus on regulatory processes for its lead candidate, PALSONIFY (paltusotine), with its PDUFA date set for September 25, 2025. The company has illustrated strong progress in its clinical programs, including advancing multiple trials and maintaining a solid cash position of $1.2 billion. Management emphasized its commitment to become a commercial-stage company while noting increasing operational costs that led to a higher net loss in the recent quarter. Despite these challenges, Crinetics aims to deliver transformative therapies for endocrine-related diseases.
Read more →CRNXCrinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
Crinetics Pharmaceuticals announced new long-term data on PALSONIFY™ (paltusotine), showing its effectiveness in controlling IGF-1 levels and reducing symptom burden in acromegaly patients during the ENDO 2025 conference. The data from ongoing open-label extensions of the PATHFNDR-1 and PATHFNDR-2 studies indicate a strong safety profile and stable symptom management. These findings provide additional support for PALSONIFY's potential as a leading treatment option for acromegaly patients as it approaches its PDUFA date.
Read more →CRNXCrinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
Crinetics Pharmaceuticals announced that it will report its second quarter 2025 financial results on August 7, 2025, following the market's close. Management will host a conference call at 4:30 p.m. ET to discuss these results and provide a business update. The company is focused on developing therapeutics for endocrine diseases, with key candidates currently in clinical development.
Read more →CRNXCrinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announced the grant of stock options and restricted stock units (RSUs) to 46 new non-executive employees. This decision was made under the 2021 Employment Inducement Incentive Award Plan, as permitted by Nasdaq Listing Rule 5635(c)(4). A total of 102,350 shares in stock options and 77,875 RSUs were awarded, with vesting conditions tied to continued employment. This move reflects Crinetics' strategy to attract talent as it progresses in developing novel therapeutics for endocrine diseases.
Read more →CRNXCrinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline Long-term efficacy and safety data on PALSONIFY TM (paltusotine) in acromegaly to be pres
Crinetics Pharmaceuticals is set to showcase eight presentations at ENDO 2025 in San Francisco, including data on its lead drug candidate, PALSONIFY (paltusotine), for treating acromegaly. The conference will highlight long-term efficacy and safety results from pivotal trials, alongside promising Phase 2 trial results of atumelnant for congenital adrenal hyperplasia. Additionally, new early-stage data on conditions such as Graves' hyperthyroidism will also be presented, underpinning Crinetics' commitment to addressing unmet needs in endocrinology.
Read more →CRNXPatient Focused Drug Development
Crinetics is committed to integrating patient insights into every stage of drug development, from discovery to commercialization. This patient-centric approach aims to create therapies that are not only clinically effective but also meaningful in everyday life. By listening to patients, Crinetics adapts its protocols and trial designs to better meet their needs, ultimately enhancing the overall experience and impact of their therapies.
Read more →CRNXThis presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you
Crinetics Pharmaceuticals presented its strategic focus and development plans during a recent event. The company highlighted multiple ongoing clinical trials and emphasized the potential of its pipeline, including treatments for neuroendocrine tumors and polycystic kidney disease. Despite promising advancements, Crinetics cautioned stakeholders about inherent risks associated with clinical trials and regulatory approvals. The company remains optimistic about its financial positioning and growth trajectory, planning several public updates as it develops therapies.
Read more →CRNXCrinetics Pharmaceuticals to Host R&D Day on June 26, 2025
Crinetics Pharmaceuticals announced that it will host an R&D Day in New York on June 26, 2025. The event will present updates on the company's pipeline assets, including discussions on treatments for diseases such as Graves’ disease and autosomal polycystic kidney disease. The agenda includes a live question-and-answer session to encourage interaction with attendees. This initiative highlights Crinetics’ commitment to transparency and engagement with the investment community.
Read more →CRNXCrinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals, Inc. has announced the grant of stock options and restricted stock units under its 2021 Employment Inducement Incentive Award Plan. On June 10, 2025, a total of 74,000 stock options and 48,850 RSUs were awarded to 20 new non-executive employees. These awards serve as inducements for new hires in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are designed to vest over a four-year period, contingent on the employees' continued employment with the company.
Read more →CRNXUnderstanding the Role of IGF-1 in Managing Acromegaly
The article discusses the importance of IGF-1 in managing acromegaly, highlighting its role as a stable indicator of disease activity. Regular IGF-1 testing is crucial for monitoring treatment effectiveness and guiding adjustments. While achieving target IGF-1 levels can lead to improved health outcomes, some patients may still face symptoms despite normal readings. Ongoing research is necessary to enhance understanding and management strategies.
Read more →CRNXAcromegaly Awareness Day: Our Support to the Community Today and Beyond
On Acromegaly Awareness Day, Crinetics highlights its commitment to developing new treatments for acromegaly, a rare endocrine disease affecting around 27,000 patients in the U.S. The company has submitted a New Drug Application to the FDA for an innovative oral therapy designed to improve symptom control without painful injections. Crinetics expresses gratitude to the patient community for their support and involvement in clinical trials.
Read more →CRNXCelebrating Women’s Leadership: Crinetics’ Commitment to Scientific and Strategic Excellence
Jacqui Kirby, the new Chief Corporate Affairs Officer at Crinetics Pharmaceuticals, reflects on the importance of women leaders in the pharmaceutical industry. She emphasizes the need for effective communication between scientists, patients, and investors to translate scientific breakthroughs into impactful narratives. Kirby advocates for curiosity and personal presence as key components of successful leadership and communication.
Read more →CRNXCrinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
Crinetics Pharmaceuticals, Inc. announced its participation in the upcoming Jefferies Global Healthcare Conference 2025, scheduled for June 3-5 in New York, NY. The company will present on June 5, showcasing their innovative therapeutics focused on endocrine diseases. Crinetics’ lead candidate, paltusotine, is being developed for acromegaly and neuroendocrine tumors, while Atumelnant targets congenital adrenal hyperplasia and Cushing's syndrome. Their presence at this conference emphasizes the company's commitment to advancing medicine in this specialized area.
Read more →CRNXCrinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
Crinetics Pharmaceuticals is set to present two significant abstracts at the AACE Annual Meeting 2025 in Orlando, FL, highlighting research on paltusotine and the burden of acromegaly symptoms. Paltusotine, an investigational treatment, reportedly achieved rapid and sustained IGF-1 control in surgically naive acromegaly patients. Additionally, a real-world evidence analysis reveals high discontinuation rates with current standard-of-care therapies for acromegaly, underscoring the need for improved treatment options. The findings are complemented by insights into another investigational candidate, atumelnant, which is focused on managing Cushing’s syndrome.
Read more →CRNX▲ +8.6%on this newsshared move
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announced the granting of stock options and restricted stock units (RSUs) to new employees on May 10, 2025. The awards consist of 152,475 stock options and 101,800 RSUs, aimed at recruiting talent as per Nasdaq Listing Rule 5635(c)(4). These options will vest over a four-year period, contingent on continued employment. The initiative reflects the company's efforts to enhance its workforce as it develops therapeutics for endocrine diseases.
Read more →CRNXCrinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Applicatio
Crinetics Pharmaceuticals reported its Q1 2025 financial results, revealing a net loss of $96.8 million, which is a larger loss compared to the previous year. Despite this, the company remains on track for the FDA review of paltusotine, with a PDUFA date set for September 25, 2025, and is also progressing with multiple late-stage clinical studies. The company highlighted positive outcomes from its atumelnant study and plans for an R&D Day on June 26, 2025, to discuss its early-stage pipeline.
Read more →CRNX▲ +8.4%on this news
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
Crinetics Pharmaceuticals has announced that it will report its first quarter 2025 financial results on May 8, 2025, after market close. Following the report, management will host a conference call to discuss the results and provide a business update. The company is engaged in developing novel therapies for endocrine diseases, including its lead candidate paltusotine for acromegaly and carcinoid syndrome. This event demonstrates the company’s commitment to keeping investors informed about its financial progress and drug developments.
Read more →CRNXCrinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announced the granting of stock options and restricted stock units to 26 new non-executive employees under its 2021 Employment Inducement Incentive Award Plan. This award includes a total of 124,950 stock options and 84,725 RSUs, with their vesting structured over four years. The initiatives are intended to attract and retain talent while complying with Nasdaq Listing Rule 5635(c)(4). Crinetics continues its focus on developing novel therapeutics for endocrine diseases and related tumors.
Read more →CRNXCrinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
Crinetics Pharmaceuticals announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for paltusotine, aimed at treating acromegaly. This submission marks a crucial milestone in Crinetics' efforts to make its therapies globally accessible. Paltusotine has shown promising results in clinical trials, meeting all endpoints in Phase 3 studies. Additionally, it has received Orphan Drug Designation from the EMA, underscoring the urgent need for effective treatments in acromegaly.
Read more →CRNXCrinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announced the granting of stock options and restricted stock units (RSUs) to new employees as part of its 2021 Employment Inducement Incentive Award Plan. The awards include a total of 95,675 stock options for fifteen non-executive employees and 80,000 options for one new executive. Additionally, 40,775 RSUs were granted to non-executive employees and 52,000 to an executive employee. These grants aim to bolster recruitment and align employee interests with stock performance under Nasdaq Listing Rule 5635(c)(4).
Read more →CRNXCrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Commercial Preparations On-Track Ahead of
Crinetics Pharmaceuticals reported its fourth quarter and full-year financial results for 2024, highlighting a strong cash position of $1.4 billion with a runway into 2029. The company is prepared for the expected launch of paltusotine for acromegaly, with anticipated initiation of four late-stage trials in 2025. While the firm noted increased net losses and expenses, key leadership appointments were made to drive future growth and development. Management is optimistic about the upcoming milestones and advances in their clinical pipeline.
Read more →CRNX▼ -7.6%on this newsshared move
Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer SAN DIEGO –
Crinetics Pharmaceuticals has appointed Tobin Schilke as Chief Financial Officer effective February 28, 2025. With over 25 years of experience in the biopharma sector, Schilke has a track record of transforming biotech companies, including his recent tenure at Revance Therapeutics. His leadership is expected to be crucial as Crinetics approaches its first commercial launch and continues development of its investigational drug candidates. Share awards and stock options will be granted as part of his inducement to join the company.
Read more →CRNXCrinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
Crinetics Pharmaceuticals, Inc. announced its participation in two upcoming investor conferences in March. The TD Cowen 45th Annual Healthcare Conference will be held in Boston, MA, while the Leerink Global Healthcare Conference will take place in Miami, FL. Management will engage in fireside chats at both events, and webcasts will be available on the company's website. The participation reflects Crinetics' commitment to investor relations and showcases its pipeline of innovative therapies.
Read more →CRNXCrinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announced the granting of stock options and restricted stock units to 14 new non-executive employees on February 10, 2025. Under the 2021 Employment Inducement Incentive Award Plan, a total of 105,100 shares were allocated as stock options and 9,950 as RSU awards. These grants are part of a strategy to attract talent to the company, which focuses on developing novel therapeutics for endocrine diseases. The stock options and RSUs will vest over a four-year period contingent on the employees' ongoing employment.
Read more →CRNXCrinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Crinetics Pharmaceuticals has announced it will report its fourth quarter and full year 2024 financial results on February 27, 2025, following the market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results and provide an update on business activities. As a clinical-stage pharmaceutical company, Crinetics is focused on developing novel therapeutics for various endocrine diseases, including its investigational drug paltusotine.
Read more →CRNX▼ -8.6%on this news
Safe Harbor Statement This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our
Crinetics Pharmaceuticals, Inc. presented a forward-looking statement during the J.P. Morgan Healthcare Conference, highlighting its plans for clinical development of its drug candidates, atumelnant and paltusotine. The company reported a strong financial position with approximately $1.4 billion in cash and investments, and recent successes in clinical trials for both drug candidates, indicating great potential in treating endocrine diseases. Despite sharing positive milestones, the company acknowledged potential risks such as regulatory approval challenges and reliance on external partners for development.
Read more →CRNX▼ -16.3%on this newsshared move
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announced the grant of stock options amounting to 196,100 shares for new employees under its 2021 Inducement Plan. This initiative is aligned with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent by offering non-qualified stock options. The options have an exercise price set at $40.59 per share, equal to the closing price on the grant date. The shares will vest over four years, encouraging long-term employment among the new staff.
Read more →CRNX▼ -16.3%on this newsshared move
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Acros
Crinetics Pharmaceuticals announced positive topline results from the Phase 2 trial of atumelnant for congenital adrenal hyperplasia (CAH). The study reported substantial and statistically significant reductions in key biomarkers including androstenedione. Participants experienced meaningful improvements in symptoms of CAH, supporting the initiation of a Phase 3 trial. The drug has shown a favorable safety profile with no severe adverse events recorded during the trial.
Read more →CRNX▼ -5%on this news· ran to -24% by day 3shared move
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Crinetics Pharmaceuticals, Inc. will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 4:30 p.m. Pacific Time. CEO Scott Struthers will share insights on the company's ongoing development of novel therapeutics, including their lead candidate, paltusotine, for treating acromegaly and carcinoid syndrome. The event will be accessible via a live webcast and later archived on the company's website. Crinetics continues to focus on addressing various endocrine conditions through its innovative drug pipeline.
Read more →CRNXCrinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer SAN DIEGO –
Crinetics Pharmaceuticals has appointed Isabel Kalofonos as the new Chief Commercial Officer. In her role, she will spearhead the company's commercial strategy for the anticipated launch of paltusotine, the first oral treatment for acromegaly. Kalofonos brings more than 20 years of industry experience and is expected to strengthen the company’s market presence. Her previous success in launching innovative therapies is anticipated to benefit Crinetics as it works towards delivering new treatments for endocrine disorders.
Read more →CRNX▲ +5.2%on this newsshared move
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announced the granting of stock options to 16 new non-executive employees as part of its 2021 Employment Inducement Incentive Award Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). Each stock option allows for the purchase of shares at an exercise price equal to the market closing price on December 10, 2024. The vesting schedule spans four years, encouraging employee retention and commitment. This initiative reflects the company's efforts to attract new talent and enhance its workforce.
Read more →CRNXCrinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly FDA Assigns a Prescription Drug User Fee Act Target Action Date of
Crinetics Pharmaceuticals has announced that the FDA has accepted its New Drug Application for paltusotine, which is aimed at treating adults with acromegaly. If approved, paltusotine will be the first oral selective somatostatin receptor type 2 agonist available for this condition, providing an alternative to injectable treatments. The FDA has set a target action date for the review of the application on September 25, 2025. The NDA submission included data from Phase 3 clinical trials demonstrating the drug's efficacy in managing acromegaly symptoms.
Read more →CRNX▼ -8.3%on this news
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) will participate in three investor conferences in December 2024, including the Piper Sandler, Citi Global Healthcare, and Evercore HealthCONx conferences. Management will be available for fireside chats and one-on-one meetings to discuss the company's developments in therapeutics for endocrine diseases. Notably, their lead candidate, paltusotine, is in Phase 3 clinical development for acromegaly and shows promise for carcinoid syndrome. These engagements reflect Crinetics' strategic approach to investor relations and awareness.
Read more →CRNXCrinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update Submission of New Drug Application for Paltusotine for the Treatment of Acromegaly Completed Upsized Public Offering of
Crinetics Pharmaceuticals has reported its third quarter 2024 financial results, highlighting the submission of a New Drug Application for its investigational drug paltusotine, which is being developed for the treatment of acromegaly. The company also successfully completed a $575 million upsized public offering to bolster its financial resources. Furthermore, they are preparing to present data on their first drug candidate from a novel nonpeptide drug conjugate platform at the upcoming NANETS conference. Despite reporting a net loss of $76.8 million, the company remains optimistic about future developments and the anticipated launch of paltusotine in 2025.
Read more →CRNXCrinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
Crinetics Pharmaceuticals announced the presentation of two abstracts at the upcoming North American Neuroendocrine Tumor Society Annual Meeting. The company will showcase preclinical data for its lead candidate CRN09682, a novel nonpeptide drug conjugate aimed at treating SST2-expressing tumors. Additionally, findings from a Phase 2 trial of paltusotine, which demonstrated efficacy in reducing carcinoid syndrome symptoms, will be highlighted. These advancements reflect Crinetics' ongoing commitment to enhancing treatment options for neuroendocrine tumors and related conditions.
Read more →CRNXCrinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announced the granting of 99,500 stock options to eleven new non-executive employees on November 10, 2024. This move is part of the company's 2021 Employment Inducement Incentive Award Plan. The stock options, with an exercise price aligned with the recent closing stock price, are aimed at incentivizing new hires to join the company and will vest over four years. This initiative reflects Crinetics' continued growth and commitment to developing novel therapeutics for endocrine diseases.
Read more →CRNXCrinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
Crinetics Pharmaceuticals, Inc. has announced that it will release its financial results for the third quarter of 2024 on November 12, 2024, after market close. A conference call will be held at 4:30 p.m. ET on the same day to discuss the results and provide a business update. The event will be accessible via dial-in or live webcast. Crinetics is focused on developing novel therapeutics for endocrine diseases, including its lead candidate, paltusotine, which is in advanced stages of clinical development.
Read more →CRNXCrinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announced the grant of non-qualified stock options to 27 new non-executive employees as part of their 2021 Employment Inducement Incentive Award Plan. These stock options, amounting to 258,800 shares, have an exercise price matching the current market price of $51.78. The options will vest over a four-year period, promoting long-term employment and retention. This initiative aligns with Nasdaq Listing Rule 5635(c)(4), reinforcing Crinetics' commitment to growth and development in the biopharma sector.
Read more →CRNXCrinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Crinetics Pharmaceuticals has announced the pricing of an upsized public offering of 10 million shares at $50 each. This initiative is expected to generate gross proceeds of $500 million, which will be allocated to fund clinical development and general corporate purposes. The offering is set to close on or about October 10, 2024, pending customary closing conditions. Additionally, there's a 30-day option for underwriters to purchase an extra 1.5 million shares.
Read more →CRNXCrinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly SAN DIEGO –
Crinetics Pharmaceuticals has submitted a New Drug Application (NDA) to the U.S. FDA for paltusotine, aimed at treating acromegaly. This marks a significant step forward, supported by comprehensive data from 18 clinical trials, including two Phase 3 studies that met all primary and secondary endpoints. Paltusotine is designed as a once-daily oral therapy and represents a major advancement in treatment options for the acromegaly community. The FDA's response to the NDA submission is anticipated in December 2024, potentially paving the way for a new standard of care.
Read more →CRNXCrinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announced the grant of stock options to 15 new non-executive employees under its 2021 Employment Inducement Incentive Award Plan. The stock options, totaling 120,200 shares, were awarded as inducements for joining the company, adhering to Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $50.40 per share and will vest over four years. This initiative highlights Crinetics' strategy to attract skilled professionals while focusing on their clinical-stage drug development efforts.
Read more →CRNXCrinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Crinetics Pharmaceuticals, a clinical stage pharmaceutical company, announced its participation in two upcoming investor conferences in New York: the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 and the Cantor Global Healthcare Conference on September 18. The events provide opportunities for the company to engage with investors and present developments in its therapeutic pipeline. Crinetics is focused on novel treatments for endocrine diseases, with investigational drugs such as paltusotine and atumelnant in clinical development.
Read more →CRNXCrinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announced the granting of non-qualified stock options to 15 new non-executive employees, totaling 103,900 shares, under its 2021 Employment Inducement Incentive Award Plan. This grant, in accordance with Nasdaq Listing Rule 5635(c)(4), aims to attract new talent as part of the company's ongoing growth strategy. The stock options, priced at $47.64 per share, will vest over a four-year period, incentivizing continued employment. This initiative reflects Crinetics' commitment to building a strong team to support its clinical-stage developments in endocrine therapies.
Read more →CRNX▲ +5.1%on this newsshared move
Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
Crinetics Pharmaceuticals has launched the ACRO/TRUTH initiative to address the challenges faced by patients with acromegaly in managing their condition using current treatments. This educational program features a dedicated website providing insights through storytelling and peer-reviewed data, with the goal of enhancing communication between healthcare providers and patients. The initiative was informed by extensive interviews with patients and experts, highlighting the need for better understanding and management of acromegaly symptoms. By focusing on patient perspectives, Crinetics aims to create informed conversations that improve treatment outcomes.
Read more →CRNX▲ +5.1%on this newsshared move
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update Paltusotine NDA Submission in Acromegaly On Track for 2024 Topline Results from Phase 2 Studies of Atumelnant in Congen
Crinetics Pharmaceuticals reported its financial results for the second quarter of 2024, highlighting a successful ongoing development of its drug candidates. The company anticipates submitting a New Drug Application for paltusotine, aimed at treating acromegaly, later this year. Additionally, positive initial results from the atumelnant studies were presented at the ENDO 2024 conference, and further data is expected by the end of 2024. Despite a net loss for the quarter, the company's cash position remains strong at $863 million, indicating a robust financial foundation for future activities.
Read more →CRNXCrinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
Crinetics Pharmaceuticals, Inc. has announced that it will report its financial results for the second quarter of 2024 on August 8, 2024, after market close. Management will host a conference call at 4:30 p.m. ET to discuss these results and provide a business update. Interested participants can join the call via telephone or a live webcast. Crinetics Pharmaceuticals focuses on developing novel therapeutics for endocrine diseases and related tumors, with several investigational candidates currently in various stages of clinical development.
Read more →CRNX▲ +5.3%on this news
Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals has granted non-qualified stock options for 137,900 shares to eighteen new non-executive employees as part of their 2021 Employment Inducement Incentive Award Plan. This initiative aims to attract new talent in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $50.80 per share, reflecting the market price on the granting date. The options vest over four years, contingent on continued employment. Crinetics continues to progress its pipeline of new therapeutics for endocrine diseases.
Read more →CRNXCrinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announced on June 10, 2024, that it granted non-qualified stock option awards for a total of 158,000 shares to nine new non-executive employees. This move is part of the company's 2021 Inducement Plan, aimed at incentivizing individuals who are new to the organization. Each stock option has an exercise price corresponding to the closing share price on the same day and will vest over four years. This initiative highlights Crinetics' commitment to attracting new talent as it develops its innovative therapies.
Read more →CRNXCrinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
Crinetics Pharmaceuticals presented new data on its once-daily oral treatment, paltusotine, for acromegaly at ENDO 2024. The findings from the PATHFNDR-2 trial highlighted significant efficacy in achieving targeted IGF-1 levels and improving patient-reported outcomes. Additionally, long-term data from the ACROBAT Advance study showed sustained safety and symptom control over 42 months. Crinetics plans to submit a New Drug Application for paltusotine in the second half of 2024.
Read more →CRNXCrinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing s Syndrome (ADCS) 100% of
Crinetics Pharmaceuticals has reported initial findings from two Phase 2 studies of atumelnant, an oral ACTH receptor antagonist, presented at ENDO 2024. In a trial for Congenital Adrenal Hyperplasia (CAH), 100% of participants maintained androstenedione levels below the upper limit of normal, with significant reductions in both androstenedione and 17-hydroxyprogesterone levels observed. Simultaneously, participants with ACTH-dependent Cushing's syndrome (ADCS) showed normalization of urinary free cortisol levels. The ongoing studies are demonstrating promising safety and efficacy profiles, with no severe adverse events recorded to date.
Read more →CRNXCrinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
Crinetics Pharmaceuticals has appointed Dr. Robert M. Cuddihy as the new senior vice president of Medical Affairs. Dr. Cuddihy, a board-certified physician with extensive experience, will help guide the company's product candidates, including paltusotine and atumelnant, as they advance in clinical development. His role is expected to strengthen Crinetics' reputation in the medical community while focusing on addressing high unmet needs in endocrine diseases. Crinetics aims to provide innovative treatment options through its robust pipeline of therapeutics.
Read more →CRNXCrinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
Crinetics Pharmaceuticals has announced the early release of late-breaking abstracts for the ENDO 2024 meeting. The abstracts include preliminary data from a Phase 2 study of atumelnant (CRN04894) for treating Congenital Adrenal Hyperplasia. The company plans to present additional findings at the Late-Breaking Poster Presentation session on June 3, 2024. Crinetics is also advancing several other therapeutics for various endocrine diseases and tumors.
Read more →CRNXCrinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announced the granting of non-qualified stock option awards for 176,000 shares to fifteen new non-executive employees. These awards are part of the 2021 Employment Inducement Incentive Award Plan and serve as an inducement for new hires as per Nasdaq Listing Rule 5635(c)(4). The stock options are priced at $48.00 per share, equal to the closing price of Crinetics' stock on the day of the announcement, and will vest over four years.
Read more →CRNXCrinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Late-Breaking Presentations of Initial Results From Phase 2 Studies of Atumelnant (CRN04894) in Congenital Adrenal Hyper
Crinetics Pharmaceuticals has reported its financial results for the first quarter of 2024, showcasing continued success in its clinical trials. The company revealed positive results from Phase 3 studies of paltusotine in acromegaly and Phase 2 studies in carcinoid syndrome. There are plans to submit a New Drug Application for paltusotine later this year, alongside presenting initial results from atumelnant trials at ENDO 2024. Despite these successes, Crinetics is facing increases in net losses and a significant drop in revenues compared to the previous year.
Read more →CRNX▲ +6.8%on this newsshared move
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024 Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Present
Crinetics Pharmaceuticals has announced the presentation of several advancements in its development programs, including initial data from its Phase 2 trial of atumelnant for congenital adrenal hyperplasia and findings from its Phase 1b/2a trial for ACTH-dependent Cushing's syndrome. The company will also showcase data from Phase 3 PATHFNDR trials evaluating paltusotine for acromegaly at the ENDO 2024 conference. The presentations represent a significant milestone for Crinetics as it aims for a new drug application submission for paltusotine later this year.
Read more →CRNXCrinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
Crinetics Pharmaceuticals, Inc. has announced that it will report its financial results for the first quarter of 2024 on May 9, 2024, after U.S. market close. Following the report, company management will host a conference call to discuss the results and provide updates on business activities. The announcement reflects Crinetics' continuous commitment to its clinical programs and communicates important information to investors and stakeholders.
Read more →CRNXCrinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announced the grant of non-qualified stock options to ten new non-executive employees as part of its 2021 Employment Inducement Incentive Award Plan. These options, totaling 121,300 shares, were issued as inducements for individuals entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $45.90 per share and will vest over a four-year period. This move signifies the company’s focus on expanding its workforce to support its clinical development efforts in endocrine therapies.
Read more →CRNX▲ +19.1%on this news
Crinetics Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients 56% of Participants on Paltusotine Achieved IGF-1 1.0 xULN vs. 5% on Placebo (
Crinetics Pharmaceuticals announced that its oral drug paltusotine achieved the primary and all secondary endpoints in the Phase 3 PATHFNDR-2 study for treating acromegaly patients. In the study, 56% of participants on paltusotine reached a significant insulin-like growth factor 1 (IGF-1) level compared to only 5% in the placebo group. Paltusotine was generally well-tolerated without any serious adverse events, paving the way for a New Drug Application submission to the FDA expected in the second half of 2024. This promising data underlines the drug's potential to improve treatment options for acromegaly patients.
Read more →CRNXCrinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flushi
Crinetics Pharmaceuticals announced positive topline results from a Phase 2 trial of paltusotine, an oral treatment for carcinoid syndrome. The trial showed that paltusotine significantly reduced the frequency and severity of flushing episodes and was well-tolerated by participants. Following these encouraging results, the company is preparing to initiate a Phase 3 study by the end of the year. Crinetics confirmed that the recent findings align with previous positive data regarding paltusotine's efficacy.
Read more →CRNXCrinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announced the grant of non-qualified stock options to five new non-executive employees as part of its 2021 Employment Inducement Incentive Award Plan. This issuance is in accordance with Nasdaq Listing Rule 5635(c)(4) and involves options for a total of 42,450 shares at an exercise price matching the stock close on March 8, 2024. The vested options will encourage employee retention and support Crinetics' efforts in developing therapies for endocrine diseases. The company's clinical pipeline includes promising candidates for various endocrine conditions.
Read more →CRNX▲ +5.7%on this news
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
Crinetics Pharmaceuticals has announced an oversubscribed private placement of 8,333,334 shares at a price of $42.00 each, raising approximately $350 million. The offering is backed by a collection of both new and existing institutional investors, aimed at funding research and development of its clinical-stage products, among other corporate purposes. The deal is expected to close on March 1, 2024, pending customary conditions being met. This financing strategy highlights the company’s ongoing commitment to development in rare endocrine diseases and cancers.
Read more →CRNX▲ +5.7%on this news
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Phase 3 PATHFNDR-2 Study Topline Results Expected in March 2024; Pending Results, NDA Submission in Acro
Crinetics Pharmaceuticals reported its financial results for Q4 and the full year 2023, establishing a strong foundation for future growth. The company anticipates topline results from the Phase 3 PATHFNDR-2 study for its lead drug, paltusotine, in March 2024, aiming for a New Drug Application submission in the second half of 2024. The firm also announced a $350 million private placement to support operations and extend its cash runway into 2028, despite reporting a net loss of $214.5 million for 2023.
Read more →CRNXCrinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Crinetics Pharmaceuticals, Inc. announced plans to report its fourth quarter and full year 2023 financial results on February 28, 2024, following the close of U.S. markets. The company will host a conference call and webcast at 4:30 PM ET to discuss these results along with a business update. Crinetics, focused on developing therapies for endocrine diseases, is moving forward with its drug candidates in advanced clinical stages, including Paltusotine for acromegaly.
Read more →CRNXCrinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announced the grant of non-qualified stock options for 73,000 shares to nine new non-executive employees as part of their 2021 Employment Inducement Incentive Award Plan. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) to incentivize new hires. The options have an exercise price of $39.46 and will vest over four years, contingent on the employees' continued employment. This move underscores Crinetics' commitment to building its team as it advances its innovative therapeutics for endocrine diseases.
Read more →CRNXCrinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals has announced the granting of stock option awards totaling 112,500 shares to eight new non-executive employees. This initiative is part of their 2021 Employment Inducement Incentive Award Plan, designed to attract new talent under Nasdaq Listing Rule 5635(c)(4). The stock options will have an exercise price of $37.60 per share and will vest over four years, encouraging employee commitment. The company focuses on developing novel therapies for endocrine diseases.
Read more →CRNXnd 42 Annual J.P. MORGAN Healthcare Conference JA NUA RY 9 , 2 02 4 Safe Harbor Statement This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. ("Crinetics," the "company," "we," or "our"
Crinetics Pharmaceuticals presented forward-looking statements at the 42nd Annual J.P. Morgan Healthcare Conference regarding their clinical development programs. They highlighted the potential benefits of their lead drug paltusotine for treatment of acromegaly and carcinoid syndrome, citing strong Phase 3 results. The company is also anticipating upcoming data from several critical studies, including new drug applications. However, they acknowledged inherent risks and potential regulatory hurdles that could impact their timelines.
Read more →CRNXCrinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Crinetics Pharmaceuticals, Inc. will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. CEO Scott Struthers will lead the presentation, which will include a webcast accessible through the company's website. As a clinical-stage pharmaceutical company, Crinetics focuses on developing therapeutics for endocrine diseases. Their investigational drug candidates include treatments for acromegaly, Cushing's disease, and other endocrine-related conditions.
Read more →CRNXCrinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome Significant Reductions in Frequency and Intensity of Both Bowel Movements and Flu
Crinetics Pharmaceuticals has reported positive initial outcomes from its ongoing open-label Phase 2 study of paltusotine for treating carcinoid syndrome. The results indicate substantial reductions in both the frequency and intensity of bowel movements and flushing episodes among participants. Paltusotine, which was well-tolerated, will have its complete results expected in the first half of 2024. This study reinforces the potential of paltusotine as an effective treatment option for patients with carcinoid syndrome.
Read more →CRNXCrinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals has announced the granting of stock options to six new non-executive employees as part of its 2021 Employment Inducement Incentive Award Plan. This decision aligns with Nasdaq Listing Rule 5635(c)(4), aimed at incentivizing new talent. The options, which total 94,000 shares, are set at an exercise price of $33.27 and will vest over four years, providing a structured incentive for employees. The company continues to focus on developing novel therapeutics for rare endocrine diseases and related tumors.
Read more →CRNXCrinetics Pharmaceuticals to Participate in Upcoming Investor Conferences
Crinetics Pharmaceuticals, Inc. announced its participation in two upcoming investor conferences: the 6th Annual Evercore ISI HealthCONx Conference in Miami and the Piper Sandler 35th Annual Healthcare Conference in New York. Company management will engage in fireside chats at both events, aimed at providing insights into their clinical developments and initiatives. The events will be accessible via live and archived webcasts on the company's website, emphasizing Crinetics' commitment to transparency and investor relations.
Read more →CRNXCrinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced the grant of non-qualified stock options for 83,600 shares to four new employees under its 2021 Inducement Plan. This move complies with Nasdaq Listing Rule 5635(c)(4) aimed at attracting talent. The stock options have an exercise price of $26.93 per share, mirroring the closing price on November 10, 2023, and will vest over a period of four years contingent on continued employment. Crinetics is focused on developing treatments for rare endocrine diseases.
Read more →CRNXCRINETICS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED FINANCIAL STATEMENT DATA (In thousands, except per share data) (Unaudited) Three months ended September 30, Nine months ended September 30, STATEMENTS OF OPERATIONS
Crinetics Pharmaceuticals reported strong financial results for the third quarter of 2023, highlighted by the successful completion of the Phase 3 PATHFNDR-1 study for paltusotine, which met both primary and secondary endpoints. The company anticipates topline data from the ongoing PATHFNDR-2 study in early 2024 and plans to release initial Phase 2 trial data for paltusotine in carcinoid syndrome in December 2023. Financially, the company experienced a net loss increase and a slight decline in revenue, yet its recent public offering has significantly strengthened its balance sheet, expected to fund operations through 2026.
Read more →CRNXCrinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals reported its third quarter 2023 financial results, highlighting the success of the PATHFNDR-1 Phase 3 study for paltusotine in acromegaly. The company expects topline data from the ongoing PATHFNDR-2 study in early 2024 and initial data from a Phase 2 study in carcinoid syndrome by December 2023. Crinetics also announced a significant public offering that bolstered its financial position, although it reported a higher net loss compared to the previous year.
Read more →CRNXCrinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals has announced the granting of non-qualified stock option awards for a total of 619,100 shares to eleven new non-executive employees as part of their 2021 Employment Inducement Incentive Award Plan. This initiative is in accordance with Nasdaq Listing Rule 5635(c)(4), aimed at attracting talent to the company. The stock options will vest over four years, starting with a 25% vesting after one year. Crinetics remains focused on developing therapies for rare endocrine diseases and related tumors.
Read more →CRNXCrinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
Crinetics Pharmaceuticals will participate in the Cantor Global Healthcare Conference from September 26-28, 2023. Management will engage in a fireside chat and hold 1x1 investor meetings during the event. This participation showcases the company’s commitment to fostering relationships with investors and stakeholders. Crinetics is known for its work on novel therapeutics for endocrine diseases and has several drug candidates in various stages of clinical development.
Read more →CRNX▲ +63.3%on this news· ran to +92% by day 1shared move
Crinetics Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly 83% of Participants on Paltusotine Maintained IGF-1
Crinetics Pharmaceuticals announced that its once-daily oral drug, paltusotine, met the primary and all secondary endpoints in the Phase 3 PATHFNDR-1 study for treating acromegaly. An impressive 83% of participants maintained their insulin-like growth factor 1 (IGF-1) levels on paltusotine, which is significantly better than the 4% observed in the placebo group. Paltusotine was well-tolerated among participants, with no severe adverse effects reported. The company is poised to seek regulatory approval for the drug pending successful outcomes of a follow-up study.
Read more →CRNXCRINETICS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED FINANCIAL STATEMENT DATA (In thousands, except per share data) (Unaudited) Three months ended June 30, Six months ended June 30, STATEMENTS OF OPERATIONS DATA: 2023
Crinetics Pharmaceuticals reported its second-quarter 2023 financial results and provided a corporate update highlighting the progress of its PATHFNDR clinical studies for acromegaly. The company anticipates topline data from the Phase 3 PATHFNDR-1 study in September 2023 and has completed enrollment for the Phase 3 PATHFNDR-2 study, with expected results in Q1 2024. However, the firm has suspended the development of its CRN04777 program due to new nonclinical findings. The company also plans a new drug application submission for paltusotine in 2024 if data supports it.
Read more →CRNXCrinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals reported its financial results for Q2 2023 and provided updates on its clinical trials. The company anticipates topline data from the Phase 3 PATHFNDR-1 study of its treatment for acromegaly in September 2023, while enrollment for PATHFNDR-2 is completed, expecting results in early 2024. However, Crinetics has suspended the development of CRN04777 due to issues identified in nonclinical studies, which do not align with its quality standards. The net loss for the quarter rose as well, highlighting financial challenges amidst ongoing development efforts.
Read more →CRNXCrinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly
Crinetics Pharmaceuticals announced a Key Opinion Leader webinar scheduled for August 8, 2023, focusing on the treatment landscape and unmet needs in acromegaly. The webinar will feature presentations from leading experts in the field and will include discussions on the burdens of standard care treatments. Crinetics will also highlight its investigational drug, paltusotine, designed as an oral alternative to injectable therapies, aiding patients in managing this serious condition.
Read more →CRNXCrinetics to Highlight Broad Pipeline at ENDO 2023
Crinetics Pharmaceuticals will showcase its pipeline at ENDO 2023, highlighting several key presentations focused on paltusotine, an oral SST2 agonist in Phase 3 trials for acromegaly. The company will also present data on preclinical programs for treating primary hyperparathyroidism and Graves' disease. Additionally, Crinetics CEO R. Scott Struthers will receive the John D. Baxter Prize for his contributions to drug discovery in the endocrine field. Presentations will occur between June 15-18, 2023, in Chicago, Illinois.
Read more →CRNXCRINETICS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED FINANCIAL STATEMENT DATA (In thousands, except per share data) (Unaudited) Three months ended March 31, STATEMENTS OF OPERATIONS DATA: 2023 2022 Revenues $ 2,679 $ 3
Crinetics Pharmaceuticals reported its financial results for Q1 2023, noting a net loss of $46 million and a decline in revenues. The company is on track to release topline data from the PATHFNDR-1 study in the third quarter and has increased enrollment targets for the PATHFNDR-2 study. The NDA submission for paltusotine is expected in 2024, pending positive trial outcomes. Despite financial losses, Crinetics possesses sufficient cash reserves to support operations through 2024.
Read more →CRNXCrinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Phase 3 PATHFNDR-1 study topline data expected in 3Q 2023 Phase 3 PATHFNDR-2 study topline data expected in 1Q 2024 and enrollment target increased to up to 98 per prespecified protocol criteria Paltusotine’s Phase 2 study in carcinoid syndrome on track for preliminary data in
Read more →CRNXCrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Paltusotine’s Phase 3 PATHFNDR-1 study enrollment complete and topline data expected in 3Q 2023 Paltusotine’s Phase 3 PATHFNDR-2 study enrollment ongoing with topline data now expected in 1Q 2024 Pending a successful outcome from the PATHFNDR studies, an NDA submission in acrom
Read more →CRNXCRINETICS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED FINANCIAL STATEMENT DATA (In thousands, except per share data) (Unaudited) Three months ended December 31, Twelve months ended December 31, STATEMENTS OF OPERATIONS
Crinetics Pharmaceuticals reported its financial results for Q4 2022 and provided updates on its clinical programs. The company completed enrollment for the Phase 3 PATHFNDR-1 study of paltusotine in acromegaly, with topline data due in Q3 2023. A New Drug Application is anticipated in 2024 pending positive results from the PATHFNDR studies. Crinetics also reported strong advancements in its other drug candidates, with successful financial performance noted, including a $125 million stock offering.
Read more →CRNXCrinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will participate in a fireside chat at the annual SVB Securities Global Biopharma Conference, which is being held in a virtual format February 14-16, 2023
Read more →CRNX▼ -5.6%on this newsshared move
Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference
Efforts to further increase commercial readiness ongoing as Phase 3 PATHFNDR trials of paltusotine in acromegaly approach topline data readouts which are expected in 2H 2023 Phase 2 trial of paltusotine in carcinoid syndrome on track for topline data in 2H 2023 Clinical trials
Read more →CRNX▼ -5.6%on this newsshared move
SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics”) cautions you that statements contained in this presentation regarding matters that
Crinetics Pharmaceuticals is advancing its pipeline of drug candidates aimed at treating various endocrine disorders, notably through its PATHFNDR program for paltusotine. The company has protocols in place for clinical trials expected to yield significant data in 2023. However, they have issued caution regarding forward-looking statements, recognizing the inherent risks and uncertainties linked to trial outcomes and timelines. Crinetics also highlighted its commitment to developing new therapies, maintaining a focus on unmet medical needs within the endocrinology sector.
Read more →CRNX▼ -5.9%on this news
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
Crinetics Pharmaceuticals Provides Update on CRN04777 Program SAN DIEGO, November 28, 2022 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today provided an update on its development program for CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist bei
Read more →CRNXCrinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 5th Annual Evercore ISI HealthCONx Conference being held virtually November 29
Read more →CRNXThree months ended September 30, Nine months ended September 30, STATEMENTS OF OPERATIONS DATA: 2022 2021 2022 2021 License revenues $ 458 $ — $ 4,028 $ — Operating expenses: Research and development 31,987
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update Paltusotine's Phase 3 PATHFNDR-1 trial in acromegaly fully enrolled and on track for topline data in Q3 2023 Paltusotine lowered and maintained IGF-1 at levels comparable to pri
Read more →CRNXCrinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Paltusotine’s Phase 3 PATHFNDR-1 trial in acromegaly fully enrolled and on track for topline data in Q3 2023 Paltusotine lowered and maintained IGF-1 at levels comparable to prior injected SRL therapy for up to 103 weeks in participants living with acromegaly participating in th
Read more →CRNXInvestors / Media: Corey Davis LifeSci Advisors, LLC cdavis@lifesciadvisors.com (212) 915-2577 Aline Sherwood Scienta Communications asherwood@scientapr.com (312) 238-8957
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly Topline results for PATHFNDR-1 study expected in Q3 2023 SAN DIEGO October 13, 2022 Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the completion of enro
Read more →CRNXCrinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer SAN DIEGO, October 3, 2022 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of Dana Pizzuti, M.D., as chief development officer. Dr. Pizzuti is a board-certified
Read more →CRNXCrinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022, both virtually and in
Read more →CRNX(858) 450-6464 Investors / Media: Corey Davis LifeSci Advisors, LLC cdavis@lifesciadvisors.com (212) 915-2577 Aline Sherwood Scienta Communications asherwood@scientapr.com (312) 238-8957
Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Paltusotine's Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023 CRN04894 Phase 1 Data Demonstrated Phar
Read more →CRNXCrinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023 CRN04894 Phase 1 Data Demonstrated Pharmacologic Proof-of-Concept for Further Development in Both Cushing’s Disease and Congenital Adrenal Hyp
Read more →CRNXCrinetics Presents Clinical and Research Results at ENDO 2022
SAN DIEGO, June 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that results from the company’s Phase 1 study of CRN04894, the company’s investigational candidate for the treatment of Cushing’s disease, congenital adrenal hyperplasia (CAH) an
Read more →CRNX▲ +8.7%on this newsshared move
Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference
SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announ
Read more →CRNX▼ -11.6%on this news
Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts
Patient Studies in Cushing’s Disease and Congenital Adrenal Hyperplasia to Initiate Later this Year Management Hosting Webcast and Conference Call Today to Discuss Findings at 8:00 a.m. Eastern Time SAN DIEGO, May 25, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Na
Read more →CRNX▼ -11.6%on this news
This presentation contains forward-looking statements. Crinetics cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statement
CRN04894: Phase 1 Multiple ascending dose (MAD) Preliminary Results May 25, 2022 Exhibit 99.1 This presentation contains forward-looking statements. Crinetics cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-
Read more →CRNX▲ +5%on this news· ran to +26% by day 3
Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update • Phase 1 Multiple-Ascending Dose Data for CRN04894 Expected in 2Q22 • Paltusotine's Phase 3 PATHFNDR Tri
Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update -Phase 1 Multiple-Ascending Dose Data for CRN04894 Expected in 2Q22 -Paltusotine's Phase 3 PATHFNDR Trials in Acromegaly Advancing Towards Anticipated Top-Line Data Readouts in
Read more →CRNX▼ -11.8%on this news
Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering
SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announ
Read more →CRNX▲ +24.4%on this newsshared move
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering
SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announ
Read more →CRNXCrinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts
Results Further Support Clinical Proof-of-Concept for CRN04777 by Showing Dose-Dependent Decreases in Fasting and Sulfonylurea-Induced Insulin Secretion Management Hosting Webcast and Conference Call to Discuss Findings Today at 4:30 p.m. Eastern Time SAN DIEGO, March 30, 2022
Read more →CRNXCrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results – Pipeline Includes Three New Chemical Entities with Clinical Proof-Of-Concept (POC) Following CRN04894 and CRN04777 Phase 1 Re
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results Pipeline Includes Three New Chemical Entities with Clinical Proof-Of-Concept (POC) Following CRN04894 and CRN04777 Phase 1 Readouts in 2021 Advancing Phase 3 PATHFNDR Program Evaluating Paltus
Read more →CRNXCrinetics Pharmaceuticals Appoints Chris Robillard as Chief Business Officer
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today
Read more →CRNXCrinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors
Crinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors SAN DIEGO, March 14, 2022 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rar
Read more →CRNXCrinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer
Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer SAN DIEGO, March 1, 2022 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercia
Read more →CRNXCrinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter into Exclusive Licensing Agreement for the Development and Commercialization of Paltusotine in Japan
SAN DIEGO and NAGOYA, Japan, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-rela
Read more →CRNXCrinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference
SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announ
Read more →CRNXCrinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference
- Phase 1 multiple ascending dose data for CRN04894 and CRN04777 expected in 1Q 2022 – - Initiation of patient dosing in a Phase 2 trial of paltusotine in carcinoid syndrome associated with neuroendocrine tumors expected in 2022 - - Initiation of IND-enabling studies for parath
Read more →CRNXCrinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rog rio Vivaldi Coelho, M.D.
Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rog rio Vivaldi Coelho, M.D., M.B.A. SAN DIEGO, January 5, 2022 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery,
Read more →CRNXCrinetics Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
SAN DIEGO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announc
Read more →CRNXCrinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress
SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announc
Read more →CRNXCrinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Pipeline Includes Three New Chemical Entities with Clinical Proof-of-concept Following CRN04894 and CRN04777 Phase 1
Crinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Pipeline Includes Three New Chemical Entities with Clinical Proof-of-concept Following CRN04894 and CRN04777 Phase 1 Readouts - - Advancing a Parathyroid Hormone Receptor Anta
Read more →CRNXCrinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announc
Read more →CRNXCrinetics Pharmaceuticals to Unveil its Parathyroid Hormone Receptor Antagonist Program at the American Society for Bone and Mineral Research Annual Meeting
- Late-breaking Poster Presentation on Sunday, October 3, 2021 SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics
Read more →CRNXCrinetics Pharmaceuticals’ Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study
CRN04777 Phase 1 Program Progressing to Multiple Ascending Dose Cohorts to Advance Development as a Treatment for Congenital Hyperinsulinisms Demonstrated Dose-dependent Reductions in Glucose-stimulated and Sulfonylurea-induced Insulin Secretion Management Hosting Webcast to Di
Read more →CRNXCrinetics Pharmaceuticals to Participate in September Investor Conferences
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today annou
Read more →CRNXCrinetics Pharmaceuticals Expands Executive Team with Addition of Jeff Knight as Chief Operating Officer
Crinetics Pharmaceuticals Expands Executive Team with Addition of Jeff Knight as Chief Operating Officer SAN DIEGO, September 2, 2021 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commerciali
Read more →CRNXCrinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
– Commenced dosing in Phase 3 PATHFNDR-1 study – – Phase 1 single-ascending dose data demonstrate the dose-dependent and clinically-significant pharmacodynamic effects of CRN04894 – – Phase 1 data for CRN04777 expected in September – SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -
Read more →CRNXCrinetics Pharmaceuticals’ Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study
CRN04894 Phase 1 Study Progressing to Multiple Ascending Dose Cohorts Management Hosting Webcast and Conference Call Today to Discuss Findings at 4:30 p.m. Eastern Time SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage
Read more →CRNXCrinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Commenced dosing in Phase 3 PATHFNDR-1 study - - Phase 1 single-ascending dose data demonstrat
Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Commenced dosing in Phase 3 PATHFNDR-1 study - - Phase 1 single-ascending dose data demonstrate the dose-dependent and clinically-significant pharmacodynamic effects of CRN0
Read more →CRNXCrinetics Pharmaceuticals Announces $15.0 Million Private Placement with Frazier Healthcare Partners
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announc
Read more →CRNXCRINETICS PHARMACEUTICALS, INC. STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (the " Agreement ") is made as of
CRINETICS PHARMACEUTICALS, INC. STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (the "Agreement") is made as of July 28, 2021 (the "Effective Date"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and the purchasers whose names and
Read more →CRNXCrinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
- If successful, paltusotine would offer acromegaly patients a once-daily oral treatment option - SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commer
Read more →CRNXCrinetics Pharmaceuticals Appoints Garlan Adams as General Counsel
SAN DIEGO, June 16, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today
Read more →CRNXCrinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update Paltusotine Phase 3 PATHFNDR program in acromegaly initiated in 2Q 2021 Phase 1 data for CRN04894
Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update Paltusotine Phase 3 PATHFNDR program in acromegaly initiated in 2Q 2021 Phase 1 data for CRN04894 and CRN04777 expected in mid-2021 SAN DIEGO - May 6, 2021 - Crinetics Pharmac
Read more →CRNXCrinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
Paltusotine Phase 3 PATHFNDR program in acromegaly initiated in 2Q 2021 Phase 1 data for CRN04894 and CRN04777 expected in mid-2021 SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the
Read more →CRNXCrinetics Pharmaceuticals Announces Closing of Common Stock Offering
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announ
Read more →CRNXCrinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results Advancing paltusotine into a Phase 3 program for acromegaly following an FDA m
Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results Advancing paltusotine into a Phase 3 program for acromegaly following an FDA meeting Phase 1 clinical proof-of-concept data for CRN04894 and CRN04777 expected
Read more →CRNXCrinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results
Advancing paltusotine into a Phase 3 program for acromegaly following an FDA meeting Phase 1 clinical proof-of-concept data for CRN04894 and CRN04777 expected in 1H 2021 and mid-2021, respectively Management hosting webcast and conference call today at 4:30 p.m. ET SAN DIEGO,
Read more →CRNXCrinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results
SAN DIEGO, March 24, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today
Read more →CRNXCrinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today
Read more →CRNXCrinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs
- Details of New Paltusotine Tablet Formulation to be Unveiled - - Preclinical Evidence Supporting Programs in Congenital Hyperinsulinism and Congenital Adrenal Hyperplasia and Cushing’s Disease Selected for Oral and Late-breaking Presentations - SAN DIEGO, March 12, 2021 (GLOB
Read more →CRNXCrinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing’s Disease (CRN04894) Advances into Phase 1 Study
SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today
Read more →CRNXCrinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study
SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today a
Read more →CRNXCrinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference
- Paltusotine planned to advance to a pivotal Phase 3 trial in acromegaly in H1 2021 - - Initiation of Phase 1 proof-of-concept study evaluating CRN04894 for the treatment of congenital adrenal hyperplasia and Cushing’s disease expected in January 2021 - - Initiation of Phase 1
Read more →CRNXCrinetics Pharmaceuticals to Participate in December Investor Conferences
SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that company management will participate in the following conferences in the month of December. Please see additional details below: Evercore ISI 3 rd Annual HealthCONx Confere
Read more →CRNXCrinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today a
Read more →CRNXCrinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for the Treatment of Acromegaly
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today a
Read more →CRNXCrinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trials of oral paltusot
Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trials of oral paltusotine for the treatment of acromegaly CRN04777 received Rare Pediatric Disease De
Read more →CRNXCrinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trials of oral paltusotine for the treatment of acromegaly CRN04777 received Rare Pediatric Disease Designation for the treatment of congenital hyperinsulinism SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) --
Read more →CRNXThis presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements, including statements regarding: the potential
Topline Results from the Acrobat Phase 2 program in Acromegaly October 26, 2020 Exhibit 99.1 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements, including s
Read more →CRNXCrinetics Pharmaceuticals Announces Phase 2 ACROBAT Edge Study with Paltusotine in Acromegaly Met Primary Endpoint
ACROBAT Edge Results Showed Maintenance of IGF-1 Suppression with Paltusotine After Switching from Depot Somatostatin Receptor Ligand Monotherapy Paltusotine was observed to be well tolerated among the 60 participants in the ACROBAT Edge and Evolve Studies On Track to Initiate
Read more →CRNXCrinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today
Read more →CRNXCrinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at European Congress of Endocrinology
SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today
Read more →CRNXCrinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D., to Board of Directors
Crinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D., to Board of Directors SAN DIEGO - September 3, 2020 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commerc
Read more →CRNXCrinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update Paltusotine received Orphan Drug Designation for the treatment of acromegaly Half of the enrolle
Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update Paltusotine received Orphan Drug Designation for the treatment of acromegaly Half of the enrolled patients in the ongoing Phase 2 ACROBAT Edge clinical trial for paltusotine h
Read more →CRNXCrinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Paltusotine received Orphan Drug Designation for the treatment of acromegaly Half of the enrolled patients in the ongoing Phase 2 ACROBAT Edge clinical trial for paltusotine had completed the study as of June and topline data is expected in fourth quarter 2020 Reported positive
Read more →CRNXCrinetics Pharmaceuticals Receives Orphan Drug Designation for Paltusotine for the Treatment of Acromegaly
SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today a
Read more →CRNXCrinetics Pharmaceuticals Confirms Completion for Half of the Enrolled Patients in the Ongoing Phase 2 ACROBAT Edge Clinical Trial for Paltusotine
28 patients have completed the open-label Edge trial measuring IGF-1 levels after 13 weeks of treatment when patients with acromegaly were switched to once daily oral paltusotine from commercially available depot injections of the peptide somatostatin receptor ligands (SRLs) Rec
Read more →CRNXCrinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update Reported positive interim results for the ACROBAT Edge Phase 2 trial of oral paltusotine in the t
Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update Reported positive interim results for the ACROBAT Edge Phase 2 trial of oral paltusotine in the treatment of acromegaly Completed successful public offering raising net proceed
Read more →CRNXCrinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
Reported positive interim results for the ACROBAT Edge Phase 2 trial of oral paltusotine in the treatment of acromegaly Completed successful public offering raising net proceeds of $107.9 million SAN DIEGO, May 08, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasda
Read more →CRNXCrinetics Pharmaceuticals Reports Positive Interim Results for the ACROBAT Edge Phase 2 Trial of Paltusotine (CRN00808) in Acromegaly Patients and Provides Corporate Update
Data from initial patients who have completed the ongoing open label Edge trial show that IGF-1 levels were maintained after 13 weeks of treatment when patients were switched to once daily oral paltusotine from commercially available depot injections of the peptide somatostatin r
Read more →CRNXSAFE HARBOR STATEMENT This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements, including statements re
Interim Results from the Open Label ACROBAT Edge Phase 2 Study and Corporate Update Exhibit 99.1 SAFE HARBOR STATEMENT This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-loo
Read more →CRNXCrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today
Read more →CRNXCrinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today a
Read more →CRNXCrinetics Pharmaceuticals to Participate in the Piper Jaffray Healthcare Conference
SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today a
Read more →CRNXCrinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today r
Read more →CRNXCrinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference
SAN DIEGO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today
Read more →CRNXCrinetics Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today
Read more →CRNXCrinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update SAN DIEGO - August 13, 2019 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization
Read more →CRNXCrinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism
SAN DIEGO, July 29, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today
Read more →CRNXCrinetics Pharmaceuticals Appoints Stephanie Okey to Board of Directors
Crinetics Pharmaceuticals Appoints Stephanie Okey to Board of Directors SAN DIEGO, July 16, 2019 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare e
Read more →CRNXCrinetics Pharmaceuticals Initiates Phase 1 Study of CRN01941 for the Treatment of Neuroendocrine Tumors
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today a
Read more →CRNXCrinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update SAN DIEGO - May 13, 2019 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of
Read more →CRNXCrinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly
SAN DIEGO, March 19, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today
Read more →CRNXCrinetics Pharmaceuticals Appoints Gina Ford, RPh, MBA, as Vice President, Corporate Strategy and Commercial Planning
SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today
Read more →CRNXCrinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019
SAN DIEGO, March 14, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today
Read more →CRNXCrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
SAN DIEGO, March 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today
Read more →CRNXCrinetics Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
SAN DIEGO, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today a
Read more →CRNXCrinetics Pharmaceuticals to Participate in Piper Jaffray 30th Annual Healthcare Conference
SAN DIEGO, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today a
Read more →CRNXCrinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update SAN DIEGO November 13, 2018 Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization
Read more →CRNXThis presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financia
October 2018 Corporate Presentation This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business s
Read more →CRNXCrinetics Pharmaceuticals to Present at Leerink Partners Roundtable Series: Rare Disease & Oncology
SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today
Read more →CRNXCrinetics Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update SAN DIEGO August 30, 2018 Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization o
Read more →CRNXCrinetics Pharmaceuticals Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, July 20, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today an
Read more →CRNXCrinetics Pharmaceuticals Announces Pricing of Initial Public Offering
SAN DIEGO, July 17, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today an
Read more →CRNXCrinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism and Acromegaly
SAN DIEGO, June 21, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that i
Read more →CRNXCrinetics Pharmaceuticals Appoints Alan Krasner, M.D., as Chief Medical Officer
SAN DIEGO, June 18, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the ap
Read more →CRNXCrinetics Pharmaceuticals Completes $63.5 Million Series B Financing
SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced it has completed a Series B financing which raised $63.5 million in new funds. The inve
Read more →CRNXCrinetics Pharmaceuticals Announces Upcoming Presentations at ENDO 2018
SAN DIEGO, March 12, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced an oral presentation and two poster presentations relating to the company’s drug develo
Read more →CRNXCrinetics Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care Conference
SAN DIEGO, March 07, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that Scott Struthers, Ph.D., founder and chief executive officer, will present at the C
Read more →CRNXCrinetics Pharmaceuticals Appoints Marc Wilson as Chief Financial Officer
SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced the appointment of Marc Wilson to the executive team as Chief Financial Officer. “We ar
Read more →CRNXCrinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly
SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced the initiation of a Phase 1, double-blind, randomized, placebo-controlled, single- and-m
Read more →CRNXCrinetics Pharmaceuticals Awarded Two SBIR Grants to Develop New Therapeutics for Congenital Hyperinsulinism and Cushing’s Disease
SAN DIEGO, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, announced today that it was awarded two new grants from the National Institute of Diabetes and Digestiv
Read more →CRNXCrinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808
SAN DIEGO, July 13, 2017 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, announced today that it was awarded a Phase IIB Small Business Innovation Research (SBIR) grant of up to
Read more →CRNXCrinetics Pharmaceuticals Appoints Anne Klibanski, M.D. to Scientific Advisory Board
SAN DIEGO, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals ("Crinetics"), an innovative therapeutics company focused on specialty endocrine disorders and endocrine-related cancers, announced today the addition of Anne Klibanski, M.D. as a member of the company's scien
Read more →Competitive Position
How CRNX ranks across every disease it competes inCompetitive Position is a premium feature
See how CRNX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial